Is there a monthly GLP-1 shot? MariTide and berobenatide
Reviewed 23 sourcesPublished by PepVault
No monthly GLP-1 shot is approved yet. MariTide and berobenatide are in phase 3: how one shot lasts a month, what phase 2 found, and when results are due.

- Last reviewed
- Sources
- 23
- Questions
- 8
- Compounds
- 3
The short answer
Not yet: Ozempic, Wegovy, Mounjaro and Zepbound are all weekly shots. Two monthly shots are in phase 3. Amgen's MariTide took off 12% to 16% of body weight at 52 weeks in phase 2, counting everyone, and its first phase 3 weight trials are due to finish around January 21, 2027 (registry estimate). Pfizer's monthly berobenatide trial is due in May 2028.
- No monthly GLP-1 is approved; the longest-acting approved weight shots, Wegovy and Zepbound, are weekly.
- MariTide lasts because it is built on an antibody: its half-life in people is 14 to 24 days, against about a week for semaglutide.
- MariTide phase 2: 12.3% to 16.2% weight loss at 52 weeks counting everyone, 16.3% to 19.9% estimated as if everyone had stayed on it, with no plateau yet.
- MARITIME-1 and -2 have an estimated registry primary completion of January 21, 2027; no filing date has been announced.
Evidence: Moderate: randomized phase 2 trials for both drugs (MariTide's in the New England Journal of Medicine, berobenatide's from registry results and Pfizer's releases) and phase 3 under way with no result yet. Neither is approved anywhere.

Is there a monthly Ozempic or Zepbound?
No. The Wegovy injection (semaglutide) is labelled once weekly (Wegovy also comes as a daily pill), and so is Zepbound (tirzepatide)1920. A monthly shot would mean 12 injections a year instead of 52. Two companies are testing one in phase 3, the last stage of trials before a drug can be filed for approval: Amgen with MariTide (maridebart cafraglutide) and Pfizer with berobenatide (PF-08653944, first made by Metsera as MET-097i)7914.
Pfizer completed its purchase of Metsera on November 13, 2025, and described MET-097i as "a weekly and monthly injectable GLP-1 receptor agonist" about to begin phase 39. Pfizer's own trial records now name the drug berobenatide1416.

How can one shot last a month?
It comes down to half-life: the time the body takes to clear half a dose. Semaglutide's is about one week and tirzepatide's about five days1920. Both carry a fatty chain that sticks to albumin, a protein in the blood, which slows how fast they are cleared20. That is enough for a weekly shot, not a monthly one.
MariTide is built differently. Its backbone is a human antibody (a large immune-system protein) aimed at the GIP receptor. Two GLP-1 peptides are joined to it with short amino-acid links2. So one molecule does two jobs: the peptides switch the GLP-1 receptor on, which turns appetite down and slows the stomach, and the antibody blocks the GIP receptor. Tirzepatide does the opposite on GIP: it switches that receptor on. Both approaches lowered weight in people118.
The antibody is what makes it last. In Amgen's phase 1 trial in people with obesity, MariTide's half-life was 14 to 24 days, depending on whether the active, peptide-carrying form or the whole antibody was measured, and blood levels peaked 4 to 6 days after a shot2. In the same trial, weight loss held for up to 150 days after the last dose in the repeat-dose groups2.
Berobenatide takes the other road: it is a peptide like semaglutide, built with a lipid chain that Metsera's HALO platform designed for slow clearance. In its first human trial, in 125 adults, the half-life was 380 hours, about 16 days10.

What did MariTide's phase 2 trial find?
The phase 2 trial, published in the New England Journal of Medicine in 2025, gave 592 adults MariTide or placebo under the skin for 52 weeks1. Most groups had a shot every 4 weeks at 140, 280 or 420 mg; one had 420 mg every 8 weeks, and two reached 420 mg through a 4-week or 12-week step-up. These are trial doses, not a regimen anyone can follow. The trial reported two kinds of result: one counting everyone who started (the treatment-policy figure) and one estimating the result as if everyone had stayed on the drug (the efficacy figure)14.
| Group | Weight change at 52 weeks, counting everyone (placebo) | As if everyone stayed on the drug (placebo) |
|---|---|---|
| Obesity, no diabetes (465 people) | −12.3% to −16.2% (−2.5%) | −16.3% to −19.9% (−2.6%) |
| Obesity with type 2 diabetes (127 people) | −8.4% to −12.3% (−1.7%) | −12.1% to −17.0% (−1.4%) |
In the diabetes group, HbA1c (the three-month blood sugar average) fell by 1.2 to 1.6 points counting everyone, against a 0.1-point rise on placebo1. Amgen reported that weight loss had not plateaued by week 524. In a second year, people who had lost at least 15% moved to lower monthly doses or one shot a quarter, and Amgen said "the large majority" kept their loss; its releases give no figures yet5.
All of these are human results. The mouse and monkey studies came first and also showed weight loss2.
What did berobenatide's phase 2 trials find?
VESPER-1 tested weekly shots with no step-up for 28 weeks in 239 adults. Its posted results show −6.4% at 0.4 mg rising to −12.5% at 1.2 mg, while the placebo group gained 1.7%, counting people while they stayed on treatment11. Against placebo, that is up to 14.1 percentage points11.
VESPER-3 is the monthly test: weekly shots to week 12, then one shot a month to week 28, with about 54 people a group. At week 28 the best group had lost 12.3% more than placebo while on treatment, and 10.5% more counting everyone; Pfizer reported no plateau12. Pfizer's phase 3 plans add a higher monthly dose12.
How does monthly compare with weekly?
| What | Wegovy (semaglutide) | Zepbound (tirzepatide) | MariTide | Berobenatide |
|---|---|---|---|---|
| How often | Weekly (label) | Weekly (label) | Every 4 weeks in trials; also every 8 weeks and quarterly | Weekly, or weekly then monthly, in trials |
| Shots a year | 52 | 52 | 13 on every-4-week dosing; 6 or 4 on the longer schedules | 12 on monthly dosing, after weekly shots at the start |
| Half-life | About 1 week19 | About 5 days20 | 14 to 24 days2 | About 16 days10 |
| How it works | GLP-1 on | GLP-1 and GIP on | GLP-1 on, GIP blocked | GLP-1 on |
| Weight loss beyond placebo, counting everyone | STEP 1: 12.4 points at 68 weeks17 | SURMOUNT-1: 11.9 to 17.8 points at 72 weeks18 | Phase 2: 9.8 to 13.7 points at 52 weeks1 | VESPER-3: 8.4 to 10.5 points at 28 weeks, the two phase 3 doses12 |
| Status (Nov 20, 2026) | Approved | Approved | Phase 3 | Phase 3 |

The weight row subtracts each placebo group's change, counting everyone who started (the tirzepatide and MariTide ranges are our own subtraction). The trials ran for different lengths, and the monthly drugs have only phase 2 numbers. MariTide's 52-week result overlaps the weekly drugs' at 68 to 72 weeks, and it was still falling at the end4. The first head-to-head, MARITIME-T2D-3, pits monthly MariTide against weekly semaglutide in about 1,300 people with type 2 diabetes; it measures HbA1c at 68 weeks and is due to finish in September 202823.
PepVault can hold a dose every 28 days (one day on, 27 off in the schedule) as easily as a weekly one, and the reminder comes on the day it falls due, so a monthly shot is not lost between months. Set reminders in PepVault
What side effects did the trials measure?
Mostly the stomach effects every GLP-1 drug brings: nausea, vomiting and constipation. In MariTide's phase 2 they came mostly with the first dose and were mostly mild; in the step-up groups nausea settled within a median of about six days and vomiting within one to two3. About 11% of the step-up groups stopped for any side effect, and under 8% for stomach ones3. Amgen found no link to changes in bone density3.
A slower start helps: phase 3 begins at 21 mg, then 35 mg and 70 mg over eight weeks before the target dose4. In a phase 1 study of that kind of low start, 22% to 24% of people vomited at some point and no one stopped for stomach side effects4. For comparison, 4.5% stopped semaglutide for stomach effects in STEP 1, and 4.3% to 7.1% stopped tirzepatide for any side effect in SURMOUNT-11718.
Berobenatide's VESPER-1 started at the full dose with no step-up. At 1.2 mg, 24 of 48 people reported nausea, against 13 of 48 on placebo11. In VESPER-3's two monthly groups that go on to phase 3, 10 people of about 108 stopped for side effects, and none on placebo12.
Commonly reported: a few queasy days after the first shot or a step up, then appetite settling lower.
When to get help Severe stomach pain that does not ease, sometimes reaching the back, or vomiting that stops you keeping fluids down, is a reason to call your clinician the same day19.
What is in phase 3, and when do the trials finish?
Each date is the registry's estimated primary completion, when the last person reaches the main measurement; results follow weeks or months later. As of November 20, 2026, neither drug has a phase 3 result.
| Trial | Who and how many | Main measure | Primary completion (estimated) |
|---|---|---|---|
| MARITIME-1, MariTide (NCT06858839)7 | 3,853 adults with obesity or overweight, no diabetes | Weight change at 72 weeks, three doses vs placebo | January 21, 2027 |
| MARITIME-2, MariTide (NCT06858878)8 | 1,105 adults with type 2 diabetes and obesity or overweight | Weight change at 72 weeks | January 21, 2027 |
| MARITIME-CV, MariTide (NCT07037433)22 | About 12,800 adults (planned) with heart disease and obesity or overweight | Heart outcomes | June 30, 2028 |
| VESPER-4, berobenatide weekly (NCT07311850)15 | 3,578 adults with obesity or overweight | Weight change at 64 weeks | September 21, 2027 |
| VESPER-6, berobenatide monthly (NCT07595549)14 | About 954 adults (planned) with obesity or overweight | Weight change at 72 weeks | May 4, 2028 |
| VESPER-SWITCH, berobenatide (NCT07845500)16 | About 660 adults (planned) now on weekly semaglutide or tirzepatide | Keeping weight off after a switch to monthly, at 32 weeks | February 16, 2028 |

Amgen is also testing fewer shots for the long run: extension trials after MARITIME-1 and -2 with monthly, every-8-week or quarterly dosing, and MARITIME-SWITCH, which moves people from weekly tirzepatide or semaglutide to MariTide every 8 weeks or quarterly. Amgen speaks of staying on MariTide with "as few as four or six doses per year"6. Our MARITIME-1 result page will carry the numbers when they are released.
When could a monthly shot reach pharmacies?
Neither company has given a filing or launch date. Amgen's November 3, 2026 results describe MARITIME-1 and -2 only as ongoing6, and Pfizer's June 2026 release names no regulatory timeline13.
What remains: phase 3 results, an FDA filing, then the review. For a new drug or biologic, the FDA's goal is to act within 10 months of a 60-day filing period, about a year in all, or about 8 months under priority review21. So, as our own reckoning and not a company forecast: if MARITIME-1 and -2 read out in 2027 and Amgen files that year, a US decision on MariTide would land in 2028 at the earliest on a standard review. Berobenatide's monthly trial finishes in May 202814, which puts a monthly berobenatide later.
Whichever shot you take, weekly now or monthly later, PepVault keeps your weight log and chart in the same app as your dose log, so you can see your own curve and bring it to your clinician. Track your weight in PepVault
Sources
- Jastreboff AM et al. Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial. N Engl J Med. 2025;393(9):843-857. PubMed 40549887
- Véniant MM et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6(2):290-303. PubMed 38316982
- Amgen. Amgen announces robust weight loss with MariTide in people living with obesity or overweight at 52 weeks in a phase 2 study. November 26, 2024. amgen.com
- Amgen. Results from Amgen's phase 2 obesity study of monthly MariTide presented at the American Diabetes Association 85th Scientific Sessions. June 23, 2025. amgen.com
- Amgen. Amgen reports fourth quarter and full year 2025 financial results. February 3, 2026. amgen.com
- Amgen. Amgen reports third quarter 2026 financial results. November 3, 2026. amgen.com
- ClinicalTrials.gov. MARITIME-1: maridebart cafraglutide in adults without type 2 diabetes who have obesity or are overweight (NCT06858839). Amgen. clinicaltrials.gov
- ClinicalTrials.gov. MARITIME-2: maridebart cafraglutide in adults with type 2 diabetes who have obesity or are overweight (NCT06858878). Amgen. clinicaltrials.gov
- Pfizer. Pfizer completes acquisition of Metsera. November 13, 2025. pfizer.com
- Metsera. Metsera reports highly competitive results from ongoing trial of novel potential once-monthly injectable GLP-1 receptor agonist MET-097. September 24, 2024. biospace.com
- ClinicalTrials.gov. VESPER-1: once-weekly MET097 in adults with obesity or overweight, phase 2b, posted results (NCT06712836). Pfizer. clinicaltrials.gov
- Pfizer. Pfizer's ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in phase 2b trial. February 3, 2026. pfizer.com
- Pfizer. Robust phase 2b efficacy and favorable tolerability support monthly dosing for Pfizer's GLP-1 RA berobenatide. June 6, 2026. pfizer.com
- ClinicalTrials.gov. VESPER-6: once-monthly PF-08653944 in adults with overweight or obesity (NCT07595549). Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. VESPER-4: MET097 once weekly in people with overweight or obesity (NCT07311850). Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. VESPER-SWITCH: switching to monthly berobenatide for maintaining weight in adults on weekly semaglutide or tirzepatide (NCT07845500). Pfizer. clinicaltrials.gov
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- Wegovy (semaglutide) prescribing information. Novo Nordisk. DailyMed, June 2026. dailymed.nlm.nih.gov
- Zepbound (tirzepatide) prescribing information. Eli Lilly. DailyMed, September 2026. dailymed.nlm.nih.gov
- FDA. PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027. fda.gov
- ClinicalTrials.gov. MARITIME-CV: maridebart cafraglutide and cardiovascular outcomes (NCT07037433). Amgen. clinicaltrials.gov
- ClinicalTrials.gov. MARITIME-T2D-3: maridebart cafraglutide once monthly versus semaglutide once weekly in type 2 diabetes (NCT07866066). Amgen. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.